VyraMed's Multi-Tissue Platform (MTP) from FetTech Found Highly Effective at Preventing VZV (Shingles) From Spreading in the Skin in NIAID-Sponsored Ex Vivo Human Skin Study
FORT LAUDERDALE, Fla., Dec. 7, 2023 /PRNewswire/ -- VyraMed and FetTech announced today initial results emerging from their ex vivo human skin study sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The study was performed to assess the safety and efficacy of the MTP technology in ex vivo human skin infected with the Varicella zoster virus, VZV, which causes shingles.
MTP powder and MTP gel were both highly effective at preventing VZV from spreading in the skin. Both formulations prevented VZV spread, even when added as late as 5 days post-infection. The skin was healthy with an intact dermal-epidermal junction, differentiated keratinocytes in the epidermis, and a highly cellular dermis. Taken together, the data presented here indicates that MTP in either powder or gel form is effective when used as a topical treatment against VZV and is safe for use on human skin.
"We are pleased with the data from the study," said Clay Fette, Co-Founder and CEO of VyraMed. "There is an urgent need to identify antiviral treatments, and we will continue to work to understand these data and the next steps on the role of the MTP technology moving forward. We appreciate NIAID selecting the MTP technology for inclusion in this important study and we're excited to continue to explore the potential broad-spectrum antiviral activity of the MTP technology."